Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adipose tissue derived mesenchymal stem cells (AD-MSCs or ADSCs) are multipotent stromal cells isolated from fat (adipose) tissue. They can differentiate into various lineages including osteoblasts (bone), chondrocytes (cartilage), myocytes (muscle), and adipocytes (fat). AD-MSCs are characterized by their fibroblast-like morphology and specific surface marker expression. They secrete a broad range of growth factors and cytokines that promote tissue repair, modulate immune responses, suppress inflammation, and support angiogenesis. Their immunomodulatory properties make them attractive for treating autoimmune diseases, graft versus host disease, orthopedic conditions like osteoarthritis, and other inflammatory or degenerative disorders. AD-MSCs are minimally immunogenic and can be obtained in higher yields from fat compared to bone marrow[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adipose tissue derived mesenchymal stem cell.